The majority of patients with type 1 diabetes who were treated with dapagliflozin, a sodium glucose cotransporter-2 inhibitor (SGLT-2) used to treat type 2 diabetes, had a significant decline in their blood sugar levels, according to a new study presented at the EASD and published in The Lancet Diabetes and Endocrinology.

DEPICT-1 (Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes) is a 24- week study and was the first global multicenter investigation of dapagliflozin to test its efficacy and safety in type 1 diabetes.

The double-blind, randomised, three-arm, phase 3 multicenter study was conducted at 143 sites in 17 countries, including the US.

Participants were 833 patients aged 18-75 who had inadequately controlled blood sugars with a mean baseline hemoglobin A1C (HbA1c) level of 8.53. The results demonstrate that when dapagliflozin was administered as an adjunct therapy in addition to the insulin it significantly improved outcomes.

“Our paper provides the initial signal that dapagliflozin is safe and effective in patients with type 1 diabetes and is a promising adjunct treatment to insulin to improve glycemic control,” said senior author Paresh Dandona, Chief of endocrinology, diabetes and metabolism in the Department of Medicine in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo.

“The 24-week results from DEPICT-1 are important as they represent the first Phase 3 trial in type 1 diabetes of the newer, selective SGLT-2 class of diabetes medicines as an oral adjunct to insulin.” In the study, approximately half of the patients taking dapagliflozin reduced their HbA1C levels by more than 0.5% without experiencing hypoglycemia.